Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily vs Twice-daily RT in LD-SCLC
NCT02337712Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2015
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT02337712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337712.